This medication is generally used in the therapeutic domain for conditions presenting with systemic or localized discomfort from advanced prostate cancer. It is applied across domains where additional symptomatic support is needed alongside other treatments. Flutamida is primarily used to address these conditions. The drug plays a role in managing these conditions by helping to control the growth of cancer cells, which contributes to easing the overall symptom load. It is relevant for easing symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.

It is also commonly used to address symptom escalation when initiating other long-term treatments. It is applied in addressing groups of symptoms that may appear suddenly or intensify over time, such as those related to physical discomfort or functional stress. This assists with maintaining functional stability and supports general well-being.

“This is relevant for easing the symptomatic distress associated with acute or episodic changes that may occur at the start of treatment.”

Quick Fact: Relief for Symptom Escalation Flutamida is considered relevant when short-term symptomatic assistance is needed to mitigate the temporary physiological imbalance that may occur when starting other long-term hormonal treatments.

Regulatory References

1. NIH MedlinePlus overview of Flutamide

Eligibility Profile for Flutamida Cinfa

Flutamida Cinfa is officially indicated for and restricted to the adult male population. Eligibility is defined by stringent regulatory criteria concerning age, gender, and pre-existing medical conditions.

---

Contraindications: Who Must Not Use

Use is absolutely contraindicated for certain populations, as mandated by regulatory authorities:

• Women (including those who are pregnant or breastfeeding, as the product is not indicated for this gender).
• Patients with known hypersensitivity to flutamide or any component of the preparation.
• Patients with severe hepatic impairment at baseline (liver enzyme levels significantly above normal).

---

Conditional Use and Restrictions

The medicine is not authorized for pediatric use; safety and efficacy in patients under 18 years of age are not established. Use requires caution and additional monitoring in specific groups:

• Patients with impaired renal function or cardiac disease.
• Patients with certain blood conditions, such as G6PD deficiency or hemoglobin M disease, or those who are smokers.

The interaction profile of Flutamide is strictly defined by government regulatory documentation to establish clear constraints for co-administration with other medicines or substances. These restrictions are categorized by their official impact on pharmacodynamics, pharmacokinetics, and toxicity risk.

Documented Drug and Substance Interaction Patterns

Interacting Substance	Official Regulatory Outcome
Oral Anticoagulants (e.g., Warfarin)	Increases in prothrombin time are documented, requiring close monitoring and potential dose adjustment of the anticoagulant.
Theophylline	Co-administration results in increased plasma concentrations of Theophylline due to a metabolic interaction involving the CYP 1A2 enzyme.
QT-Prolonging Drugs	Caution is required due to the potential for an additive pharmacodynamic effect on the QT interval when combined with Androgen Deprivation Therapy.

Administration and Toxicity Constraints

Flutamide administration is subject to procedural constraints when initiating combined treatment: it should commence at least 3 days before an LHRH agonist. The profile contains restrictions on substances with additive toxicity risk; excessive consumption of alcohol should be avoided due to known potential for liver and renal toxicities. Concomitant use of potentially hepatotoxic drugs requires a formal risk-benefit assessment. The medicine is contraindicated in patients with severe liver impairment (Child Pugh C). Food has no effect on the bioavailability of the medicine.

Direct Blockade of Androgen Receptor Signaling

The drug's active form, 2-hydroxyflutamide, functions as a selective competitive antagonist at the Androgen Receptor (AR). This molecular action constitutes the mechanism for antiandrogenic modulation at the cellular level by occupying the binding site and preventing the attachment of native androgens like Dihydrotestosterone (DHT).

Suppression of Androgen-Dependent Gene Expression

By blocking the AR, the drug interrupts the genetic signaling cascade, stopping the receptor complex from entering the cell nucleus and activating gene transcription. This suppression of the Androgen-Dependent Pathway results in the termination of transcription signals necessary for androgen-driven cell proliferation.

Indirect Modulation of the HPG Hormonal Axis

The blockade of ARs also affects the central Hypothalamic-Pituitary-Gonadal (HPG) axis, disrupting the natural negative feedback mechanism. This systemic disruption leads to a compensatory increase in Luteinizing Hormone (LH) release, although the sustained peripheral receptor blockade remains the dominant action.

How to Use Flutamida Cinfa: Administration Guidelines

This section outlines the specific administration and dosing protocols for Flutamida Cinfa (Flutamide). The information provided describes the established parameters for usage.

---

Dosing and Administration

Instruction	Details
Route of Administration	The only approved method is oral administration via the tablet form.
Standard Dosing	The standard regimen is 250 mg (one tablet) taken three times daily (TID), totaling 750 mg per day.
Frequency	Doses are to be spaced approximately eight hours apart to maintain consistent blood levels.
Intake Conditions	Tablets may be taken with or without food; however, they must be swallowed whole with water and should not be crushed or chewed.

---

Procedural Rules and Timing

Correct use of Flutamida is often governed by specific timing relative to other treatments:

• Initiation with LHRH Agonists: When used alongside an LHRH agonist (another type of hormonal therapy), Flutamida should be started at least 1 to 3 days prior to the first administration of the LHRH agonist.
• Adjuvant to Radiation: For localized disease, the standard dose should begin eight weeks prior to the start of external beam radiation and continue throughout the radiation course.
• Missed Dose: If a dose is missed, do not take a double dose to compensate. Patients should skip the forgotten dose and resume the normal dosing schedule at the next scheduled time.

Note on Population Use: The standard adult dose applies to older adults. However, use in patients with hepatic or renal impairment requires careful medical assessment and monitoring.

Research Evidence / Overview of Studies for Flutamida Cinfa

---

Evidence for Use in Locally Advanced and Metastatic Prostate Cancer

The main body of research for Flutamide focuses on its use in men with locally advanced or metastatic prostate cancer. The evidence comes primarily from large, multi-center Randomized Controlled Trials (RCTs) and subsequent meta-analyses, which systematically review and pool the data from these trials. This research examined the difference in measurements when Flutamide was used in addition to standard primary hormonal treatment.

Researchers in these trials focused heavily on measuring two key outcomes: Overall Survival (OS) and Progression-Free Survival (PFS). They also monitored the levels of the Prostate-Specific Antigen (PSA) biomarker, as changes in this level often reflect patterns observed during the study period.

The findings from these controlled studies were not entirely uniform. While some studies reported patterns where the combined treatment group recorded measurements related to median survival duration, other major trials reported very mixed findings or non-significant differences in final survival measurements. This variability means the certainty remains low regarding the difference in long-term measurements associated with Flutamide in this combination setting.

---

Documented Research Gaps and Uncertainties

Despite the large volume of research, several limitations and uncertainties have been noted in scientific literature. One key gap is that the findings were mixed across some of the most rigorous trials, creating some uncertainty regarding the consistency of the findings for one specific outcome (overall survival) when the drug is used in combination.

Furthermore, the research for Flutamide is often discussed in relation to studies involving newer agents, meaning comparative evidence is lacking against newer agents. The follow-up durations were limited in some smaller studies, and the overall evidence quality varies across studies when comparing different research designs, highlighting what is known — and what is still uncertain.

Common questions about Flutamida Cinfa (FAQ)

---

Q: What kind of stomach issues are common with Flutamida Cinfa?

Official product information indicates that the most commonly reported gastrointestinal issues are diarrhea, nausea, and vomiting. Less frequent stomach issues that have been reported include abdominal pain, constipation, and dyspepsia (indigestion).

---

Q: Does Flutamida Cinfa affect blood pressure?

Regulatory data reports that hypertension (high blood pressure) has been observed as an uncommon adverse reaction in a small percentage of patients taking this medication.

---

Q: Can Flutamida Cinfa cause changes in mood or energy levels?

Yes, official safety information indicates that effects on the Central Nervous System (CNS) are possible, though uncommon. These reported reactions can include drowsiness, confusion, depression, anxiety, and nervousness.

---

Q: What happens if I forget to take a dose of Flutamida Cinfa?

If a dose is missed, regulatory guidance is clear: do not take a double dose to try and make up for the one that was forgotten. Patients are instructed to skip the forgotten dose and then take the next scheduled dose at its normal time.

---

Q: Will I need regular blood tests while on Flutamida Cinfa?

Yes, regulatory documents require mandatory and regular monitoring of Liver Function Tests (LFTs), especially early in treatment. Additionally, tests for Prostate-Specific Antigen (PSA) and certain blood disorders may be necessary to monitor the drug's effects.

---

Q: Can taking Flutamida Cinfa affect my liver function?

Official regulatory warnings highlight that flutamide is associated with a risk of severe hepatic injury (liver damage), which can be serious. For this reason, liver function is required to be closely and regularly monitored before and throughout treatment.

---

Q: What are the long-term side effects of using Flutamida Cinfa?

In addition to the common hormonal side effects, continued monitoring of liver function is necessary with long-term use. Furthermore, there have been rare reports of malignant breast neoplasms (a type of breast cancer) associated with prolonged flutamide use in men.

---

Q: Does Flutamida Cinfa affect fertility in men?

Studies on flutamide monotherapy (when used alone) have shown that it can cause reduced sperm counts. Periodic sperm monitoring may be considered for patients receiving long-term treatment who have not had a medical or surgical castration.

---

Q: Can Flutamida Cinfa interact with supplements like St. John's Wort or Omega-3?

The drug's breakdown in the body can be affected by other substances. Regulatory information advises caution, as supplements like St. John’s Wort are known to interact with medicines that use the same enzyme system, potentially affecting drug levels.

---

Q: Why do doctors often prescribe Flutamida Cinfa with another medication?

Flutamida is typically used in combination with an LHRH agonist (another hormonal therapy) to enhance the effects of medical castration. The antiandrogen is started a few days earlier to help mitigate the hormonal flare—a temporary surge in testosterone that can occur when starting the LHRH agonist.

---

Q: Can Flutamida Cinfa affect sleep patterns?

Official regulatory data reports that difficulty sleeping, specifically insomnia, has been observed as an uncommon adverse reaction (less than 1% incidence) in patients taking this medication.

---

Q: What is the average time for the medication to reach its maximum concentration in the blood?

Pharmacokinetic studies indicate that the active form of the medicine, 2-hydroxyflutamide, typically reaches its maximum concentration in the bloodstream (at steady state) about 1 to 2 hours after an oral dose.

---

Q: Are there specific symptoms that warrant immediate medical attention while on Flutamida Cinfa?

Official regulatory information requires immediate medical attention for symptoms suggestive of liver problems. These symptoms include jaundice (yellowing of the skin or eyes), dark urine, severe fatigue, flu-like symptoms, or pain in the upper right abdomen. Other serious reactions, like signs of a blood disorder called methemoglobinemia, should also be reported immediately.

---

Q: Is it necessary to use birth control while taking Flutamida Cinfa, even if not sexually actively?

The drug carries a potential risk of fetal harm. For this reason, contraception is generally required during treatment. The drug is strictly contraindicated in women of childbearing age.

---

Q: What are the potential effects of accidentally taking too much Flutamida Cinfa?

In cases of suspected overdose, symptoms that have been reported include breast enlargement and tenderness. The single acute toxic dose in humans is not established, and it is stated that if an overdose is suspected, a poison control center should be contacted immediately.

Storage and Disposal of Flutamida Cinfa

The storage and disposal of Flutamida Cinfa tablets are governed by official regulatory standards to maintain product integrity and ensure public safety.

Storage Requirements

Flutamida Cinfa must be stored at a temperature not exceeding 25 °C. The tablets have an officially labeled shelf-life of 5 years and must not be used after the expiration date indicated on the package. As a mandatory safety requirement, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, Flutamida Cinfa and its packaging must not be thrown into household waste or disposed of via drains. Unused or expired medication must be returned to a designated pharmacy collection point for proper pharmaceutical waste handling.